Opiant Pharmaceuticals and Aptar Pharma Expand Long Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
By, Admin1 min read
Share
Opiant Pharmaceuticals, Inc. today announced a capacity investment agreement with Aptar Pharma (Aptar), a leading provider of drug delivery systems, to expand production of Aptar
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
